In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...

The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...

Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.

Lenacapavir, a twice-yearly injectable antiretroviral, reduced the risk of HIV infection by 96% in a large study of gay and bisexual men and gender diverse people, according to a Gilead Sciences ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...

1. In this randomized cluster trial, twice-yearly azithromycin distribution reduced all-cause childhood mortality among children aged one to 59 months in rural communities in Niger. 2. Distribution of ...